A “Trojan horse” for obesity: why GLP‑1/GIP linked to intracellular PPAR signaling looks different — and why human trials are the real test
New preclinical work from Helmholtz Munich describes a conjugate drug that uses GLP‑1/GIP receptors to carry a pan‑PPAR activator (lanifibranor)…